Cancer Gene Therapy

Primary Brain Tumors Susceptible to Genetically Engineered HSV

Published in Cancer Weekly, November 4th, 1996

Genetically engineered gamma₁ 34.5 negative herpes simplex virus (HSV) vectors have potential therapeutic value against central nervous system tumors.

Due to the lack of an effective therapy against primary brain tumors, investigators have been exploring novel experimental approaches that involve the use of vectors and recombinant viruses. These therapeutic approaches have been both indirect, whereby vectors are used to transfect therapeutic genes, and direct, whereby direct cell killing is mediated by an introduced virus.

Samita S. Andreansky et al. evaluated a genetically engineered HSV vector as an experimental approach to directly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-11-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry